Education
1992.09~1997.07 Bachelor Degree, Department of Clinical Medicine, Tianjin Medical University, Tianjin, P.R. China
1997.09~2000.07 M.S., Department of Immunology, Tianjin Medical University, Tianjin, P.R. China
2005.09~2008.07 Ph.D., Department of Oncology, Tianjin Medical University, Tianjin, P.R. China
Professional Experiences
2000.07~2003.09 Research Assistant, Department of Immunology and Cancer Biotherapy, Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China
2003.09~2008.09 Assistant Professor, Department of Immunology and Cancer Biotherapy, Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China
2008.09~2009.05 Associate Professor, Assistant director, Department of Immunology and Cancer Biotherapy, Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China
2009.05~2009.11 Exchanging researcher, Johnson & Johnson Pharmaceu- tical Research and Development (Janssen Pharmaceutica N.V.), Beerse, Belgium
2009.12~2013.03 Associate Professor, Director of the TMUCIH-JnJ joint laboratory, PI of Department of Immunology and Cancer Biotherapy, Cancer Institute & Hospital, Tianjin Medical resUniversity, Tianjin, China
2013.03~2013.11 Associate Professor, Director of Cancer Molecular Diagnostic Center, Director of the TMUCIH-JnJ joint laboratory, PI of Department of Immunology and Cancer Biotherapy, Cancer Institute & Hospital, Tianjin Medical resUniversity, Tianjin, China
2013.11~present Professor, Director of Cancer Molecular Diagnostic Center, Director of the TMUCIH-JnJ joint laboratory, PI of Department of Immunology and Cancer Biotherapy, Cancer Institute & Hospital, Tianjin Medical resUniversity, Tianjin, China
Research Focus
Professor Jinpu Yu Ph.D. is the director of the Cancer Molecular Diagnostics Core (CMDC) who started her career in Tianjin Medical University Cancer Institute & Hospital in 2000. Since 2013, Prof. Yu has been responsible for CMDC and pioneered the clinical application of next generation sequencing technology in cancer early diagnosis and individualized therapy with her academic research team. Prof. Yu has been engaged in exploring new means of anti-tumor immune therapy, researching the mechanisms of immune escape in tumor microenvironment and screening novel biomarkers and molecular targets with potential clinical value in cancer prediction, early diagnosis and target therapy.
And her recent researches on tumor immunosuppressive microenvironment in breast cancer, hepatic cancer and lung cancer have been published many times in high-impact international immunology authoritative journals which were proposed as promising hotspots caused widespread discussion among reviewers and readers. In the past five years, Prof. Yu has presided over and participated in 10 national research projects and 2 international cooperation programs, published more than 60 SCI papers totally and harvested 4 provincial scientific research awards.
Selected Publications
1. Zhang W, Jiang M, Chen J, Zhang R, Ye Y, Liu P, Yu W, Yu J. SOCS3 Suppression Promoted the Recruitment of CD11b+Gr-1-F4/80-MHCII- Early-Stage Myeloid-Derived Suppressor Cells and Accelerated Interleukin-6-Related Tumor Invasion via Affecting Myeloid Differentiation in Breast Cancer. Front Immunol. 2018 Jul 23;9:1699. PMID:30083161.https://www.frontiersin.org/articles/10.3389/fimmu.2018.01699/full
2. Jiang M, Chen J, Zhang W, Zhang R, Ye Y, Liu P, Yu W, Wei F, Ren X, Yu J. Interleukin-6 Trans-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells via Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer. Front Immunol. 2017 Dec 15;8:1840. PMID: 29326716.https://www.frontiersin.org/articles/10.3389/fimmu.2017.01840/full
3. Tian X, Wei F, Wang L, Yu W, Zhang N, Zhang X, Han Y, Yu J, Ren X. Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2.Front Immunol. 2017 Oct 30;8:1426. PMID:29163501.https://www.frontiersin.org/articles/10.3389/fimmu.2017.01426/full
4. Jiang M, Zhang WW, Liu P, Yu W, Liu T, Yu J. Dysregulation of SOCS-Mediated Negative Feedback of Cytokine Signaling in Carcinogenesis and Its Significance in Cancer Treatment. Front Immunol. 2017 Feb 8;8:70. PMID: 28228755.https://www.frontiersin.org/articles/10.3389/fimmu.2017.00070/full
5. Xiao P, Long X, Zhang L, Ye Y, Guo J, Liu P, Zhang R, Ning J, Yu W, Wei F, Yu J. Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells. Oncoimmunology. 2018 Mar 13;7(7):e1440166. PMID: 29900041.https://www.tandfonline.com/doi/full/10.1080/2162402X.2018.1440166
6. Dong L, Wu N, Wang S, Cheng Y, Han L, Zhao J, Long X, Mu K, Li M, Wei L, Wang W, Zhang W, Cao Y, Liu J, Yu J, Hao X. Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing. Hum Mutat. 2018 Oct;39(10):1442-1455. PMID: 30039884.https://onlinelibrary.wiley.com/doi/full/10.1002/humu.23597
7. Yu J, Wang Y, Yan F, Zhang P, Li H, Zhao H, Yan C, Yan F, Ren X. Noncanonical NF-κB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J Immunol. 2014 Sep 1;193(5):2574-86. PMID: 25063873.https://www.jimmunol.org/content/193/5/2574
8. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X.Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. PMID: 23440412.https://www.jimmunol.org/content/190/11/5341.2
9. Cheng Y, Wang S, Han L, Liu P, Li H, Ren X, Yu J, Hao X.Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and pathological types in solid tumors. Oncotarget. 2017 Aug 7;8(40):68746-68757. PMID: 28978153.http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=19975&path[]=63747
10. Ye Y, Long X, Zhang L, Chen J, Liu P, Li H, Wei F, Yu W, Ren X, Yu J. NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma. Oncotarget. 2016 Oct 25;7(43):70303-70322. PMID: 27611941.http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=11854&path[]=38837